Bramble Bio Signs 18-Month Manufacturing Agreement With VERIGRAFT for P-TEV Clinical Trial
- Bramble Bio (FamiCord AG's CDMO brand) will conduct technology transfer and GMP manufacturing of P-TEV, a tissue-engineered vein, at its Warsaw, Poland facility.
- The ~18-month collaboration supports VERIGRAFT's TECVI-2 Phase II/III trial launching Q1 2027 across Spain, Poland, and the Netherlands; contract value estimated in low single-digit millions of euros.
Operational Impact
Bramble Bio's Warsaw facility gains a high-complexity cell and tissue-engineering manufacturing contract supporting a pivotal Phase II/III trial, demonstrating capacity for personalized biological grafts and donor-tissue sourcing across three European markets.
Source: PharmaSource RSS